Jun 27, 2019

VivaGel® BV launched in Europe

VivaGel® BV launched in Europe
  • VivaGel® BV has been launched in Europe by Mundipharma, under the brand name Betadine BVTM
  • Betadine BVTM will be available Over-The-Counter, without prescription
  • Mundipharma is rolling out Betadine BVTM throughout Europe during the year
  • European launch triggers a milestone payment of US$0.5M (A$0.72M)
  • Starpharma is eligible to earn total milestones up to US$24.7M, plus revenue share, for all territories under Mundipharma’s licence
  • Regulatory activities are underway for multiple countries across other Mundipharma regions

Melbourne, Australia; 27 June 2019: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VivaGel® BV has been launched in Europe under the brand name Betadine BVTM. The product has been launched in several countries in Europe, including Germany, with further roll-out in additional European countries during the year.

Betadine BVTM will be available over-the-counter (OTC), without the need to see a doctor or obtain a prescription. Europe is the second region to launch VivaGel® BV and represents a large commercial opportunity with access to more than 260 million women.

VivaGel® BV (Betadine BVTM) is a novel, non-antibiotic therapy for treatment and prevention of bacterial vaginosis (BV). BV is the most common vaginal condition worldwide and twice as common as thrush. VivaGel® BV (Betadine BVTM) is an Australian innovation –invented, fully developed and taken through to commercialisation by Starpharma.

BV is a troublesome and often recurrent condition that causes unpleasant vaginal odour and discharge symptoms that have significant social impacts for women. BV has also been associated with a range of other serious reproductive health-related medical problems.

Betadine BVTM is being marketed by Mundipharma, a leading global pharmaceutical company which owns the successful international brand BETADINE®. Mundipharma is one of the largest privately-owned pharmaceutical companies in the world employing over 8,600 people.

The launch of Betadine BVTM in Europe triggers a milestone payment of US$0.5M (A$0.72M) to Starpharma.  Starpharma is eligible to earn total milestones up to US$24.7M, plus revenue share, for all territories under Mundipharma’s licence.

Dr Jackie Fairley, Starpharma CEO, commented: “We are delighted to achieve another territory launch of VivaGel® BV this year, and our first with Mundipharma. Europe represents a very important market for VivaGel® BV and we’re delighted that our breakthrough product will be available to millions of European women who suffer from BV. Mundipharma have a excellent track record in the OTC space and a leading position in feminine care with their successful international brand BETADINE®. We look forward to working with Mundipharma on further registrations and launches across the globe”.

Raman Singh, Mundipharma CEO, commented: “We are delighted to launch Betadine BVTM in Europe. This product represents a true innovation in the management of bacterial vaginosis (BV). It sits well under the BETADINE® brand, which has emerged as a powerful brand platform for consumer healthcare products, trusted by women globally.”

Starpharma’s and Mundipharma’s marketing and regulatory teams continue to work actively together on further launches of VivaGel® BV in Europe and also in other regions, such as Asia. Regulatory activities are underway for multiple countries across Mundipharma’s regions.

Download ASX Announcement: VivaGel® BV launched in Europe (PDF, 70kb)

 This contains certain forward-looking statements.